Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Retinal Diseases HELP
Based on 43,598 articles published since 2010
|||| 17 

These are the 43598 published articles about Retinal Diseases that originated from Worldwide during 2010-2020.
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Guidelines for the Management of Retinal Vein Occlusion by the European Society of Retina Specialists (EURETINA). 2019

Schmidt-Erfurth, Ursula / Garcia-Arumi, José / Gerendas, Bianca S / Midena, Edoardo / Sivaprasad, Sobha / Tadayoni, Ramin / Wolf, Sebastian / Loewenstein, Anat. ·Department of Ophthalmology, Medical University of Vienna, Vienna, Austria, ursula.schmidt-erfurth@meduniwien.ac.at. · Hospital Universitari Vall d'Hebron, Barcelona, Spain. · Department of Ophthalmology, Medical University of Vienna, Vienna, Austria. · Department of Ophthalmology, University of Padua, Padua, Italy. · Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom. · Department of Ophthalmology, Lariboisière Hospital Paris, Paris, France. · Department of Ophthalmology, Inselspital, University of Bern, Bern, Switzerland. · Department of Ophthalmology Tel Aviv Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. ·Ophthalmologica · Pubmed #31412332.

ABSTRACT: The high prevalence of cardiovascular disease particularly in the elderly population is associated with retinal vascular disease. Retinal vein occlusions represent severe disturbances of the hypoxia-sensitive neurosensory retina. Acute and excessive leakage leads to the diagnostic hallmarks of retinal hemorrhage and edema with substantial retinal thickening. Advanced diagnostic tools such as OCT angiography allow to evaluate retinal ischemia and identify the risk for late complications and will soon reach clinical routine besides fluorescein angiography. Accordingly, the duration of non-perfusion is a crucial prognostic factor requiring timely therapeutic intervention. With immediate inhibition of vascular leakage, anti-VEGF substances excel as treatment of choice. Multiple clinical trials with optimal potential for functional benefit or a lesser regenerative spectrum have evaluated aflibercept, ranibizumab, and bevacizumab. As retinal vein occlusion is a chronic disease, long-term monitoring should be individualized to combine maintenance with practicability. While steroids may be considered in patients with systemic cardiovascular risk, surgery remains advisable only for very few patients. Destructive laser treatment is an option if reliable monitoring is not feasible. Ophthalmologists are also advised to perform a basic systemic workup to recognize systemic concomitants. The current edition of the EURETINA guidelines highlights the state-of-the-art recommendations based on the literature and expert opinions in retinal vein occlusion.

2 Guideline ACOG Practice Bulletin No. 201: Pregestational Diabetes Mellitus. 2018

Anonymous26500969. · ·Obstet Gynecol · Pubmed #30461693.

ABSTRACT: Pregestational diabetes mellitus represents one of the most challenging medical complications of pregnancy because of the need for frequent monitoring and adjustment of medications as well as the potential for maternal and fetal complications. This document provides an overview of the current understanding of pregestational diabetes mellitus and suggests management guidelines during pregnancy. Because few well-designed studies have been performed, many of the guidelines are based on expert and consensus opinion. This document has been updated to reflect current data on pregestational diabetes. This Practice Bulletin is updated with summary information to counsel and manage women with pregestational diabetes before and during pregnancy, more recent literature reflecting experience with continuous subcutaneous insulin infusion during pregnancy, an expanded section on the role of oral hypoglycemic agents in pregnancy, and the option of long-acting reversible contraception during the postpartum period.

3 Guideline [Update from France Macula Federation: Treatment of Wet AMD]. 2018

Tick, S / Cornut, P-L / De Bats, F / Wolf, B / Souied, E H / Cohen, S Y. ·Centre hospitalier national d'ophtalmologie des XV-XX, 28, rue de Charenton, 75012 Paris, France; Centre ophtalmologique Vincennes, 17, bis rue des Meuniers, 94300 Vincennes, France. · Centre pôle vision, clinique du Val d'Ouest, Croix rousse, 39, chemin de la Vernique, 69130 Écully, France. · Centre pôle vision, clinique du Val d'Ouest, Croix rousse, 39, chemin de la Vernique, 69130 Écully, France; Hôpital de la Croix-Rousse, 103 grande rue de la Croix-Rousse, 69004 Lyon, France. · Centre ophtalmologique de la maison rouge, 6, rue de l'Église, 67000 Strasbourg, France. · Service d'ophtalmologie et université Paris Est, 61, avenue du Général de Gaulle, 94000 Créteil, France. · Service d'ophtalmologie et université Paris Est, 61, avenue du Général de Gaulle, 94000 Créteil, France; Centre ophthalmologique d'imagerie et de laser, 11, rue Antoine Bourdelle, 75015 Paris, France. Electronic address: sycsyc75@gmail.com. ·J Fr Ophtalmol · Pubmed #30361178.

ABSTRACT: PURPOSE: To update the recommendations of the France Macula Federation for treatment of wet age-related macular degeneration (AMD). METHODS: Analysis of literature and expert opinion. RESULTS: The FFM recommends initiating anti-VEGF therapy as soon as possible after diagnosis of exudative AMD. There has been no major change in the last several years concerning the procedure of intravitreal injection itself. However, the litigious points are discussed: simultaneous bilateral injection; antibiotic therapy; medico-legal aspects. All anti-VEGF strategies possess advantages and limitations. The strategy should be left to the ophthalmologists' preference. However, the chosen strategy should be explained to patients and strictly followed. CONCLUSION: The treatment of wet-AMD is more precisely codified than before. However, various strategies still coexist.

4 Guideline [Update from France Macula Federation: Diagnosis of wet AMD]. 2018

Wolff, B / De Bats, F / Tick, S / Cornut, P-L / Souied, É / Cohen, S Y. ·Centre ophtalmologique de la maison rouge, 6, rue de l'Église, 67000 Strasbourg, France. · Centre Ophtalmologique pôle vision, 69130 Ecully, France; Hôpital de la Croix-Rousse, 69004 Lyon, France. · Centre hospitalier national d'ophtalmologie des XV-XX, 28, rue de Charenton, 75012 Paris, France. · Centre Ophtalmologique pôle vision, 69130 Ecully, France. · Service d'ophtalmologie, université Paris Est, 94000 Créteil, France. · Centre hospitalier national d'ophtalmologie des XV-XX, 28, rue de Charenton, 75012 Paris, France; Centre ophthalmologique d'imagerie et de laser, 11, rue Antoine-Bourdelle, 75015 Paris, France. Electronic address: sycsyc75@gmail.com. ·J Fr Ophtalmol · Pubmed #30348597.

ABSTRACT: PURPOSE: To update the recommendations of the France Macula Federation for the diagnosis of wet age-related macular degeneration (AMD). METHODS: Analysis of literature and expert opinion. RESULTS: The FMF recommends diagnosing wet AMD by combining the results of fundus examination (or color or monochromatic fundus photographs), optical coherence tomography (OCT) showing exudative signs, and morphological visualization of the neovascular membrane, which may be obtained non-invasively (OCT-angiography) or invasively (fluorescein and/or indocyanine green angiography). Under optimal conditions in which all these tools are available, the FMF recommends using non-invasive methods as first-line tools and resorting to dye angiography if diagnostic doubt remains. CONCLUSION: As observed in other fields of medical imaging, non-invasive methods are preferred to invasive methods for the diagnosis of wet AMD, while the latter are reserved for more difficult cases.

5 Guideline The Royal College of Ophthalmologists recommendations on screening for hydroxychloroquine and chloroquine users in the United Kingdom: executive summary. 2018

Yusuf, Imran H / Foot, Barny / Galloway, James / Ardern-Jones, Michael R / Watson, Sarah-Lucie / Yelf, Cathy / Burdon, Michael A / Bishop, Paul N / Lotery, Andrew J. ·Oxford Eye Hospital, West Wing, John Radcliffe Hospital, Headington, Oxford, OX3 9DU, UK. · The Royal College of Ophthalmologists, 18 Stephenson Way, Kings Cross, London, NW1 2HD, UK. · Department of Rheumatology, King's College Hospital NHS Foundation Trust, Denmark Hill, London, SE5 9RS, UK. · Department of Dermatology, University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton, Hampshire, SO16 6YD, UK. · Royal Berkshire Hospital, London Road, Reading, Berkshire, RG1 5AN, UK. · The Macular Society, Crown Chambers, South St, Andover, Hampshire, SP10 2BN, UK. · Queen Elizabeth Hospital, Mindelsohn Way, Edgbaston, Birmingham, B15 2GW, UK. · Manchester Royal Eye Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester, M13 9WL & School of Biological Sciences, University of Manchester, Manchester, M13 9PL, UK. · Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, SO16 6YD, UK. A.J.Lotery@soton.ac.uk. ·Eye (Lond) · Pubmed #29887605.


6 Guideline [Recommendations for the use of ranibizumab in diabetic macular edema at IMSS]. 2017

Ortiz-Lerma, Roberto / González-Cervantes, Carlos Pedro / Hernández-Núñez, Fabiola / Ancona-Durán, Irene / Betesh-Rodríguez, Isaac / Méndez, Noé / Garza-Cantú, Daniel / López-Martínez, Óscar / Martínez-Ruiz, Adriana Marcela / López-Montero, Luis Miguel / Muñoz, Armando / Blancas-Ontiveros, Jorge Alberto / Fernández-Trejo, Carlos Mariano / Mayorga-Rubalcava, Juan Carlos / Flores-Góngora, Silvia Elizabeth / Gómez-Galván, Jorge Luis / Domínguez-Álvarez, Patricia Armida / Sánchez-Hernández, Erik / Cantú-Yeverinon, Homero. ·aJefatura del Servicio de Oftalmología, Hospital General "Dr. Gaudencio González Garza", Centro Médico Nacional La Raza, Ciudad de México. ·Rev Med Inst Mex Seguro Soc · Pubmed #29190870.

ABSTRACT: Diabetic macular edema can occur at any stage of diabetic retinopathy. It represents the main cause of vision loss in diabetes type I and II with a prevalence of 3-10% in diabetic patients of the Instituto Mexicano del Seguro Social (IMSS). Our aim is to elaborate treatment guidelines and provide recommendations for the use of intravitreal ranibizumab for diabetic medical edema at IMSS. Nine retina specialists and 10 ophthalmologists from IMSS high specialty medical units gathered to discuss the bibliographic evidence for the safety and efficacy of ranibizumab for this disease, in order to create consensus on its use in the institution. Intravitreal ranibizumab injection should be used on patients presenting diffuse or cystic diabetic macular edema who have strict metabolic control and visual acuity between 20/30 and 20/200 ETDRS, as well as structural features, such as inferior foveal limit of 280 μm and ischemic areas no larger than 50% of the central foveal area. Treatment regime should consist of a loading charge of three monthly injections of ranibizumab 0.5 mg, followed by monthly follow-ups and treatment as needed according to anatomic and functional criteria. This consensus decision-making process on the criteria to treat and re-treat patients with this drug will result in better health outcomes than those currently observed among patients with diabetic macular edema at IMSS.

7 Guideline Excerpt from the Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of diabetic retinopathy. 2017

Hooper, Philip / Boucher, Marie Carole / Cruess, Alan / Dawson, Keith G / Delpero, Walter / Greve, Mark / Kozousek, Vladimir / Lam, Wai-Ching / Maberley, David A L. ·Philip Hooper, London, ON (Chair) (retina and uveitis); Marie Carole Boucher, Montreal, QC (retina and teleophthalmology); Alan Cruess, Halifax, NS (retina); Keith G. Dawson, Vancouver, BC (endocrinology); Walter Delpero, Ottawa, ON (cataract and strabismus); Mark Greve, Edmonton, AB (retina and teleophthalmology); Vladimir Kozousek, Halifax, NS (medical retina); Wai-Ching Lam, Toronto, ON (retina and research); David A.L. Maberley, Vancouver, BC (retina). ·Can J Ophthalmol · Pubmed #29074014.

ABSTRACT: -- No abstract --

8 Guideline Management della retinopatia diabetica e dell'edema maculare diabetico: linee guida "Euretina 2017". 2017

Turchetti, P / Librando, A / Angelucci, F / Carlesimo, S C / Migliorini, R. ·Istituto Nazionale per la promozione della salute delle popolazioni Migranti ed il contrasto delle malattie della Povertà. (INMP/NIHMP), Rome 00153, Italia. · Dipartimento Organi di Senso, Facoltà di Medicina e Odontoiatria, Sapienza Università di Roma, Italia. · Centro specialistico di Salute Aurelia S.R.L., Roma, Italia. ·Clin Ter · Pubmed #29044359.

ABSTRACT: Si prevede che la malattia diabetica con tutte le sue complicanze avrà un forte aumento di incidenza con un grosso impatto socioeconomico nei prossimi decenni in tutto il mondo. Pertanto ben si comprende l'importanza di individuare attraverso una fine diagnostica quanto più precocemente la comparsa dei sintomi diabetici, migliorare lo stile di vita ed impostare cure efficienti. Riportiamo la serie di raccomandazioni EURETINA 2017, dei maggiori esperti in Europa per la gestione della malattia diabetica e delle complicanze della retina. Per combattere questa "pestilenza" occorre un team medico preparato. Il trattamento laser è stato considerato sino a non molto tempo fa il Gold standard della retinopatia diabetica e dell'edema diabetico (RD e EMD). Recenti studi hanno dimostrato, invece, che si possono raggiungere risultati migliori mediante l'iniezione diretta di farmaci nella cavità vitreale. In particolare è emerso terapia di prima linea, molecole in grado di inibire il fattore di crescita endoteliale vascolare (anti VEGF) mentre non è più raccomandata la fotocoagulazione laser per il trattamento del DME. Nell'ambito delle molecole farmacologiche gli steroidi hanno mantenuto un ruolo nella gestione del DME cronicamente persistente.

9 Guideline Management of Irvine-Gass syndrome. 2017

Kodjikian, L / Bellocq, D / Bodaghi, B. ·Department of Ophthalmology, Croix-Rousse University Hospital, Hospices Civils de Lyon, University of Lyon I, 69004 Lyon, France; CNRS UMR 5510 Mateis, 69621 Villeurbanne, France. Electronic address: kodjikian.laurent@wanadoo.fr. · Department of Ophthalmology, Croix-Rousse University Hospital, Hospices Civils de Lyon, University of Lyon I, 69004 Lyon, France; CNRS UMR 5510 Mateis, 69621 Villeurbanne, France. · Service dophtalmologie, hôpital Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France. ·J Fr Ophtalmol · Pubmed #28987449.

ABSTRACT: -- No abstract --

10 Guideline The Finnish national guideline for diagnosis, treatment and follow-up of patients with wet age-related macular degeneration. 2017

Tuuminen, Raimo / Uusitalo-Järvinen, Hannele / Aaltonen, Vesa / Hautala, Nina / Kaipiainen, Sulevi / Laitamäki, Nina / Ollila, Marko / Rantanen, Jari / Välimäki, Satu / Sipilä, Raija / Laukkala, Tanja / Komulainen, Jorma / Tommila, Petri / Immonen, Ilkka / Tuulonen, Anja / Kaarniranta, Kai. ·Department of Ophthalmology, Kymenlaakso Central Hospital, Kotka, Finland. · Helsinki Retina Research Group, University of Helsinki, Helsinki, Finland. · Patient Insurance Centre, Helsinki, Finland. · Tays Eye Centre, Tampere University Hospital, Tampere, Finland. · Department of Ophthalmology, Turku University Hospital, Turku, Finland. · Department of Ophthalmology, Oulu University Hospital, Oulu, Finland. · Medical Research Center, University of Oulu, Oulu, Finland. · Department of Ophthalmology, North Karelian Central Hospital, Joensuu, Finland. · Department of Ophthalmology, Kanta-Häme Central Hospital, Hämeenlinna, Finland. · Department of Ophthalmology, Lapland Central Hospital, Rovaniemi, Finland. · Department of Ophthalmology, Satakunta Central Hospital, Pori, Finland. · Department of Ophthalmology, Päijät-Häme Central Hospital, Lahti, Finland. · The Finnish Medical Society Duodecim, Helsinki, Finland. · Department of Ophthalmology, Helsinki University Hospital, Helsinki, Finland. · Department of Ophthalmology, Kuopio University Hospital, Kuopio, Finland. · Department of Ophthalmology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland. ·Acta Ophthalmol · Pubmed #28686003.

ABSTRACT: Age-related macular degeneration (AMD) is the main cause of visual impairment in developed countries. Several improvements in the visualization of posterior segment of the eye together with the introduction of intravitreal anti-VEGF treatment have revolutionized the prognosis of the wet form of AMD (wAMD). Increasing incidence of wAMD together with the limited resources of society and of the healthcare system poses challenges for the provision and development of care. In context of these current aspects, we aimed to set evidence-based medical guidelines for diagnosis, treatment and follow-up of patients with wAMD.

11 Guideline Action on diabetic macular oedema: achieving optimal patient management in treating visual impairment due to diabetic eye disease. 2017

Gale, R / Scanlon, P H / Evans, M / Ghanchi, F / Yang, Y / Silvestri, G / Freeman, M / Maisey, A / Napier, J. ·The Action on DMO group, UK. · The York Hospital, York, UK. · Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, UK. · University Hospital, Llandough, Cardiff, UK. · Bradford Teaching Hospitals, Bradford, UK. · The Royal Wolverhampton NHS Trust, Wolverhampton, UK. · Belfast Health & Social Care Trust, Belfast, UK. · Royal Hallamshire Hospital, Sheffield, UK. · Cardiff and Vale University Health Board, University Hospital of Wales, Cardiff, UK. · Bayer, Reading, UK. ·Eye (Lond) · Pubmed #28490797.

ABSTRACT: This paper identifies best practice recommendations for managing diabetes and sight-threatening diabetic eye disease. The authors provide an update for ophthalmologists and allied healthcare professionals on key aspects of diabetes management, supported by a review of the pertinent literature, and recommend practice principles for optimal patient management in treating visual impairment due to diabetic eye disease. In people with diabetes, early optimal glycaemic control reduces the long-term risk of both microvascular and macrovascular complications. The authors propose more can and should be done to maximise metabolic control, promote appropriate behavioural modifications and encourage timely treatment intensification when indicated to ameliorate diabetes-related complications. All people with diabetes should be screened for sight-threatening diabetic retinopathy promptly and regularly. It is shown that attitudes towards treatment adherence in diabetic macular oedema appear to mirror patients' views and health behaviours towards the management of their own diabetes. Awareness of diabetic macular oedema remains low among people with diabetes, who need access to education early in their disease about how to manage their diabetes to delay progression and possibly avoid eye-related complications. Ophthalmologists and allied healthcare professionals play a vital role in multidisciplinary diabetes management and establishment of dedicated diabetic macular oedema clinics is proposed. A broader understanding of the role of the diabetes specialist nurse may strengthen the case for comprehensive integrated care in ophthalmic practice. The recommendations are based on round table presentations and discussions held in London, UK, September 2016.

12 Guideline [Guidelines from the DOG, RG and BVA: retinal artery occlusion : November 2016 status]. 2017

Anonymous5830895 / Anonymous5840895 / Anonymous5850895. · ·Ophthalmologe · Pubmed #28160122.

ABSTRACT: -- No abstract --

13 Guideline Imaging Protocols in Clinical Studies in Advanced Age-Related Macular Degeneration: Recommendations from Classification of Atrophy Consensus Meetings. 2017

Holz, Frank G / Sadda, SriniVas R / Staurenghi, Giovanni / Lindner, Moritz / Bird, Alan C / Blodi, Barbara A / Bottoni, Ferdinando / Chakravarthy, Usha / Chew, Emily Y / Csaky, Karl / Curcio, Christine A / Danis, Ron / Fleckenstein, Monika / Freund, K Bailey / Grunwald, Juan / Guymer, Robyn / Hoyng, Carel B / Jaffe, Glenn J / Liakopoulos, Sandra / Monés, Jordi M / Oishi, Akio / Pauleikhoff, Daniel / Rosenfeld, Philip J / Sarraf, David / Spaide, Richard F / Tadayoni, Ramin / Tufail, Adnan / Wolf, Sebastian / Schmitz-Valckenberg, Steffen / Anonymous1010894. ·Department of Ophthalmology, University of Bonn, Bonn, Germany. Electronic address: Frank.Holz@ukb.uni-bonn.de. · Doheny Image Reading Center, Doheny Eye Institute, Los Angeles, California. · Eye Clinic, Department of Biomedical and Clinical Sciences "Luigi Sacco," Luigi Sacco Hospital, University of Milan, Milan, Italy. · Department of Ophthalmology, University of Bonn, Bonn, Germany. · Institute of Ophthalmology, University College London, London, United Kingdom. · Department of Ophthalmology and Visual Sciences, Fundus Photograph Reading Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. · Institute of Clinical Science, The Queen's University of Belfast, Belfast, United Kingdom. · National Eye Institute, National Institutes of Health, Bethesda, Maryland. · Texas Retina Associates, Dallas, Texas. · Department of Ophthalmology, University of Alabama School of Medicine, Birmingham, Alabama. · Vitreous Retina Macula Consultants of New York, New York, New York. · Department of Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania. · Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, University of Melbourne, Department of Surgery (Ophthalmology) Melbourne, Australia. · Department of Ophthalmology, Radboud University Medical Center, Nijmegen, The Netherlands. · Department of Ophthalmology, Duke Reading Center, Duke University, Durham, North Carolina. · Department of Ophthalmology, Cologne Image Reading Center, University of Cologne, Cologne, Germany. · Institut de la Màcula and Barcelona Macula Foundation, Barcelona, Spain. · Department of Ophthalmology, St. Franziskus Hospital, Münster, Germany. · Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida. · Stein Eye Institute, David Geffen School of Medicine, University of California, Los Angeles, California. · Ophthalmology Department, Hôpital Lariboisière, AP-HP, Université Paris 7 - Sorbonne Paris Cité, Paris, France. · Moorfields Eye Hospital, London, United Kingdom. · Department of Ophthalmology, University Hospital Bern, University of Bern, Bern, Switzerland. ·Ophthalmology · Pubmed #28109563.

ABSTRACT: PURPOSE: To summarize the results of 2 consensus meetings (Classification of Atrophy Meeting [CAM]) on conventional and advanced imaging modalities used to detect and quantify atrophy due to late-stage non-neovascular and neovascular age-related macular degeneration (AMD) and to provide recommendations on the use of these modalities in natural history studies and interventional clinical trials. DESIGN: Systematic debate on the relevance of distinct imaging modalities held in 2 consensus meetings. PARTICIPANTS: A panel of retina specialists. METHODS: During the CAM, a consortium of international experts evaluated the advantages and disadvantages of various imaging modalities on the basis of the collective analysis of a large series of clinical cases. A systematic discussion on the role of each modality in future studies in non-neovascular and neovascular AMD was held. MAIN OUTCOME MEASURES: Advantages and disadvantages of current retinal imaging technologies and recommendations for their use in advanced AMD trials. RESULTS: Imaging protocols to detect, quantify, and monitor progression of atrophy should include color fundus photography (CFP), confocal fundus autofluorescence (FAF), confocal near-infrared reflectance (NIR), and high-resolution optical coherence tomography volume scans. These images should be acquired at regular intervals throughout the study. In studies of non-neovascular AMD (without evident signs of active or regressed neovascularization [NV] at baseline), CFP may be sufficient at baseline and end-of-study visit. Fluorescein angiography (FA) may become necessary to evaluate for NV at any visit during the study. Indocyanine-green angiography (ICG-A) may be considered at baseline under certain conditions. For studies in patients with neovascular AMD, increased need for visualization of the vasculature must be taken into account. Accordingly, these studies should include FA (recommended at baseline and selected follow-up visits) and ICG-A under certain conditions. CONCLUSIONS: A multimodal imaging approach is recommended in clinical studies for the optimal detection and measurement of atrophy and its associated features. Specific validation studies will be necessary to determine the best combination of imaging modalities, and these recommendations will need to be updated as new imaging technologies become available in the future.

14 Guideline Clinical Practice Guidelines for Retinitis Pigmentosa. 2016

Anonymous2450957. · ·Nippon Ganka Gakkai Zasshi · Pubmed #30079711.

ABSTRACT: -- No abstract --

15 Guideline The opinion of the Expert Group of the Polish Society of Ophthalmology on using nepafenac in the prevention of postoperative macular edema after cataract surgery in diabetic patients. 2016

Grabska-Liberek, Iwona / Bakunowicz-Łazarczyk, Alina / Malukiewicz, Grażyna / Misiuk-Hojło, Marta / Mrukwa-Kominek, Ewa / Romaniuk, Wanda / Romanowska-Dixon, Bożena / Jurowski, Piotr / Kęcik, Dariusz / Lubiński, Wojciech / Omulecki, Wojciech / Szaflik, Jerzy / Szaflik, Jacek P / Pietruszyńska, Marta / Karska-Basta, Izabella / Stafiej, Joanna / Gosławski, Wojciech. · ·Klin Oczna · Pubmed #29912514.

ABSTRACT: Nepafenac is an innovative non-steroidal anti-inflammatory drug used in ophthalmology for the prevention of macular edema after cataract surgery. Along with its anti-inflammatory effect, nepafenac has some unique properties which distinguish it from other non-steroidal anti-inflammatory drugs. It is a prodrug activated to amfenac after it penetrates through the corneal layers to the aqueous humour and the ciliary body. Having electrically neutral molecules of lipophilic properties, nepafenac does not accumulate in the cornea and does not cause its degeneration. Additionally, it quickly achieves higher concentrations in the aqueous humour as compared to other non-steroidal anti-inflammatory drugs. Nepafenac shows high selectivity and activity against COX-2 isoform, the key enzyme implicated in inducing inflammation, which is the main cause of macular edema. Furthermore, nepafenac has the unique scleral and suprachoroidal distribution pathways. Finally, its effect on the intraocular pressure is none to negligible. Nepafenac treatment should be initiated prior to cataract surgery and continued long enough to reduce the risk of late-onset macular edema. The Expert Group of the Polish Society of Ophthalmology consider using nepafenac in the prevention of post­operative macular edema in diabetic patients undergoing cataract surgery as expedient and reasonable. The proposed optimum pre- and postoperative treatment regimen can be modified for individualised therapy.

16 Guideline The Prevention and Treatment of Retinal Complications in Diabetes. 2016

Schorr, Susanne Gabriele / Hammes, Hans-Peter / Müller, Ulrich Alfons / Abholz, Heinz-Harald / Landgraf, Rüdiger / Bertram, Bernd. ·German Agency for Quality in Medicine (ÄZQ), Berlin. ·Dtsch Arztebl Int · Pubmed #28073426.

ABSTRACT: BACKGROUND: Microvascular complications of diabetes mellitus can cause retino pathy and maculopathy, which can irreversibly damage vision and lead to blindness. The prevalence of retinopathy is 9-16% in patients with type 2 diabetes and 24-27% in patients with type 1 diabetes. 0.2-0.5% of diabetics are blind. METHODS: The National Disease Management Guideline on the prevention and treatment of retinal complications in diabetes was updated according to recommendations developed by seven scientific medical societies and organizations and by patient representatives and then approved in a formal consensus process. These recommendations are based on international guidelines and systematic reviews of the literature. RESULTS: Regular ophthalmological examinations enable the detection of retinopathy in early, better treatable stages. The control intervals should be based on the individual risk profile: 2 years for low-risk patients and 1 year for others, or even shorter depending on the severity of retinopathy. General risk factors for retinopathy include the duration of diabetes, the degree of hyperglycemia, hypertension, and diabetic nephropathy. The general, individually adapted treatment strategies are aimed at improving the risk profile. The most important specifically ophthalmological treatment recommendations are for panretinal laser coagulation in proliferative diabetic retinopathy and, in case of clinically significant diabetic macular edema with foveal involvement, for the intravitreal application of medications (mainly, vascular endothelial growth factor [VEGF] inhibitors), if an improvement of vision with this treatment is thought to be possible. CONCLUSION: Regular, risk-adapted ophthalmological examinations, with standardized documentation of the findings for communication between ophthalmologists and the patients' treating primary care physicians/diabetologists, is essential for the prevention of diabetic retinal complications, and for their optimal treatment if they are already present.

17 Guideline Forming a Consensus: Data and Guidance for Physicians Treating Diabetic Macular Edema. 2016

Puliafito, Carmen A / Cousins, Scott W / Bacharach, Jason / Gonzalez, Victor H / Holekamp, Nancy M / Merrill, Pauline T / Ohr, Matthew P / Parrish, Richard K / Riemann, Christopher D. · ·Ophthalmic Surg Lasers Imaging Retina · Pubmed #27096289.

ABSTRACT: The diabetic macular edema (DME) treatment paradigm has evolved as the understanding of the disease pathology has grown. Since 2012, four pharmacotherapies have been approved by the U.S. Food and Drug Administration for the treatment of DME. First-line treatment of DME with anti-vascular endothelial growth factor [VEGF] agents has become the gold standard; however, an appreciable percentage of patients do not respond to anti-VEGF therapies. In patients who inadequately respond to anti-VEGF therapies, the underlying disease pathology may be mediated by a multitude of growth factors and inflammatory cytokines. For these patients, corticosteroids are an attractive treatment option because they not only downregulate VEGF, but also an array of cytokines. The phase 3 MEAD and FAME trials demonstrated significant visual acuity improvements associated with dexamethasone and fluocinolone acetonide, respectively, in patients with DME; however, class-specific adverse events, including increased intraocular pressure and cataract development, must be considered before use. A panel of experts gathered during the 2015 annual meeting of the American Academy of Ophthalmology for a roundtable discussion focused on patient selection and adverse event management associated with the use of the 0.19 mg fluocinolone acetonide intravitreal implant.

18 Guideline Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). 2016

Marmor, Michael F / Kellner, Ulrich / Lai, Timothy Y Y / Melles, Ronald B / Mieler, William F / Anonymous100862. ·Department of Ophthalmology and Byers Eye Institute, Stanford University School of Medicine, Palo Alto, California. · Zentrum für Seltene Netzhauterkrankungen, AugenZentrum Siegburg, Siegburg, Germany. · Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Kowloon, Hong Kong. · Department of Ophthalmology, Kaiser Permanente, Redwood City Medical Center, Redwood City, California. · Department of Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, University of Illinois, Chicago, Illinois. ·Ophthalmology · Pubmed #26992838.

ABSTRACT: BACKGROUND: The American Academy of Ophthalmology recommendations on screening for chloroquine (CQ) and hydroxychloroquine (HCQ) retinopathy are revised in light of new information about the prevalence of toxicity, risk factors, fundus distribution, and effectiveness of screening tools. PATTERN OF RETINOPATHY: Although the locus of toxic damage is parafoveal in many eyes, Asian patients often show an extramacular pattern of damage. DOSE: We recommend a maximum daily HCQ use of ≤5.0 mg/kg real weight, which correlates better with risk than ideal weight. There are no similar demographic data for CQ, but dose comparisons in older literature suggest using ≤2.3 mg/kg real weight. RISK OF TOXICITY: The risk of toxicity is dependent on daily dose and duration of use. At recommended doses, the risk of toxicity up to 5 years is under 1% and up to 10 years is under 2%, but it rises to almost 20% after 20 years. However, even after 20 years, a patient without toxicity has only a 4% risk of converting in the subsequent year. MAJOR RISK FACTORS: High dose and long duration of use are the most significant risks. Other major factors are concomitant renal disease, or use of tamoxifen. SCREENING SCHEDULE: A baseline fundus examination should be performed to rule out preexisting maculopathy. Begin annual screening after 5 years for patients on acceptable doses and without major risk factors. SCREENING TESTS: The primary screening tests are automated visual fields plus spectral-domain optical coherence tomography (SD OCT). These should look beyond the central macula in Asian patients. The multifocal electroretinogram (mfERG) can provide objective corroboration for visual fields, and fundus autofluorescence (FAF) can show damage topographically. Modern screening should detect retinopathy before it is visible in the fundus. TOXICITY: Retinopathy is not reversible, and there is no present therapy. Recognition at an early stage (before any RPE loss) is important to prevent central visual loss. However, questionable test results should be repeated or validated with additional procedures to avoid unnecessary cessation of valuable medication. COUNSELING: Patients (and prescribing physicians) should be informed about risk of toxicity, proper dose levels, and the importance of regular annual screening.

19 Guideline [Guidelines for Intravitreal Injection for Macular Diseases]. 2016

Ogura, Yuichiro / Takahashi, Kanji / Iida, Tomohiro. · ·Nippon Ganka Gakkai Zasshi · Pubmed #26987206.

ABSTRACT: The guidelines for intravitreal injections for macular diseases are listed. Indication and drug information, injection techniques, pre -and peri-injection management, and complications due to injections are stated. Safe intravitreal injections are expected as a result of following these guidelines.

20 Guideline Screening for Impaired Visual Acuity in Older Adults: US Preventive Services Task Force Recommendation Statement. 2016

Anonymous1140860 / Siu, Albert L / Bibbins-Domingo, Kirsten / Grossman, David C / Baumann, Linda Ciofu / Davidson, Karina W / Ebell, Mark / García, Francisco A R / Gillman, Matthew / Herzstein, Jessica / Kemper, Alex R / Krist, Alex H / Kurth, Ann E / Owens, Douglas K / Phillips, William R / Phipps, Maureen G / Pignone, Michael P. ·Mount Sinai School of Medicine, New York2James J. Peters Veterans Affairs Medical Center, Bronx, New York. · University of California, San Francisco. · Group Health Research Institute, Seattle, Washington. · University of Wisconsin, Madison. · Columbia University, New York, New York. · University of Georgia, Athens. · Pima County Department of Health, Tucson, Arizona. · Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts. · Independent consultant, Washington, DC. · Duke University, Durham, North Carolina. · Fairfax Family Practice, Fairfax, Virginia13Virginia Commonwealth University, Richmond. · New York University, New York. · Veterans Affairs Palo Alto Health Care System, Palo Alto, California16Stanford University, Stanford, California. · University of Washington, Seattle. · Brown University, Providence, Rhode Island. · University of North Carolina, Chapel Hill. ·JAMA · Pubmed #26934260.

ABSTRACT: DESCRIPTION: Update of the US Preventive Services Task Force (USPSTF) recommendation on screening for impaired visual acuity in older adults. METHODS: The USPSTF reviewed the evidence on screening for visual acuity impairment associated with uncorrected refractive error, cataracts, and age-related macular degeneration among adults 65 years or older in the primary care setting; the benefits and harms of screening; the accuracy of screening; and the benefits and harms of treatment of early vision impairment due to uncorrected refractive error, cataracts, and age-related macular degeneration. POPULATION: This recommendation applies to asymptomatic adults 65 years or older who do not present to their primary care clinician with vision problems. RECOMMENDATION: The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for impaired visual acuity in older adults. (I statement).

21 Guideline Recommendations for the appropriate management of diabetic macular edema: Light on DME survey and consensus document by an expert panel. 2016

Bandello, Francesco / Midena, Edoardo / Menchini, Ugo / Lanzetta, Paolo. ·Department of Ophthalmology, University Vita-Salute, San Raffaele Scientific Institute, Milan - Italy. · Department of Neuroscience-Ophthalmology, University of Padova, Padova - Italy. · University of Florence, Clinica Oculistica AOU Careggi, Florence - Italy. · Department of Medical and Biological Sciences-Ophthalmology, University of Udine, Udine - Italy. · Istituto Europeo di Microchirurgia Oculare, Udine - Italy. ·Eur J Ophthalmol · Pubmed #26776698.

ABSTRACT: PURPOSE: The Light on DME survey was designed to address several issues concerning the management of diabetic macular edema (DME) with the objective of producing practical recommendations for the appropriate treatment of this condition. METHODS: The recommendations considered aspects of DME treatment that are controversial and insufficiently supported by the evidence and were based on a consensus reached by an expert panel. Consensus was achieved by means of the Delphi method. Thirty-one Italian retinologists were asked to rate the appropriateness of a comprehensive set of scenarios typically encountered in the management of DME in clinical practice. The results of the appropriateness evaluation were analyzed by the study panel and a second assessment round was conducted for those scenarios on which no consensus was reached. RESULTS: Consensus was reached on several relevant aspects of current DME management, namely the initiation and course of treatment with anti-vascular endothelial growth factor (VEGF) therapy, assessment of the outcomes of anti-VEGF therapy based on both functional and morphologic outcomes, combination of anti-VEGF with laser therapy, and management of nonresponders to anti-VEGFs. A few issues, including the definition of DME based on novel diagnostic tools, the need for stable metabolic parameters before initiating anti-VEGF therapy, and the use of a second anti-VEFG after failure of the first anti-VEGF, proved controversial. CONCLUSIONS: A clear consensus among DME experts was reached on several relevant aspects of DME management. Based on this consensus, detailed and practical recommendations to guide ophthalmologists in the use of novel approaches to DME could be developed.

22 Guideline Retinal Vein Occlusions Preferred Practice Pattern(®) Guidelines. 2016

Pulido, Jose S / Flaxel, Christina J / Adelman, Ron A / Hyman, Leslie / Folk, James C / Olsen, Timothy W. ·Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota. · Casey Eye Institute, Oregon Health & Science University, Portland, Oregon. · Department of Ophthalmology and Visual Science, Yale School of Medicine, New Haven, Connecticut. · Division of Epidemiology, Department of Family, Population and Preventive Medicine, School of Medicine, Stony Brook University, Stony Brook, New York. · Department of Ophthalmology and Visual Sciences, University of Iowa Hospitals & Clinics, Iowa City, Iowa. · Emory Eye Center, Emory University, Atlanta, Georgia. ·Ophthalmology · Pubmed #26581559.

ABSTRACT: GUIDELINES: New evidence-based Retinal Vein Occlusions Preferred Practice Pattern® (PPP) guidelines, discussing the prognosis and risk factors of retinal vein occlusions and the treatment options.

23 Guideline Idiopathic Epiretinal Membrane and Vitreomacular Traction Preferred Practice Pattern(®) Guidelines. 2016

Folk, James C / Adelman, Ron A / Flaxel, Christina J / Hyman, Leslie / Pulido, Jose S / Olsen, Timothy W. ·Department of Ophthalmology and Visual Sciences, University of Iowa Hospitals & Clinics, Iowa City, Iowa. · Department of Ophthalmology and Visual Science, Yale School of Medicine, New Haven, Connecticut. · Casey Eye Institute, Oregon Health & Science University, Portland, Oregon. · Division of Epidemiology, Department of Family, Population and Preventive Medicine, School of Medicine, Stony Brook University, Stony Brook, New York. · Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota. · Emory Eye Center, Emory University, Atlanta, Georgia. ·Ophthalmology · Pubmed #26578445.

ABSTRACT: GUIDELINES: New evidence-based Idiopathic Epiretinal Membrane and Vitreomacular Traction Preferred Practice Pattern® (PPP) guidelines, describing recommendations for the diagnosis, treatment, and management of patients.

24 Guideline [Not Available]. 2015

Anonymous2560852 / Anonymous2570852 / Anonymous2580852. · ·Klin Monbl Augenheilkd · Pubmed #26678907.

ABSTRACT: -- No abstract --

25 Guideline [Diabetic macular edema: Diagnosis and pre-treatment work-up]. 2015

Massin, P / Baillif, S / Creuzot, C / Fajnkuchen, F / Kodjikian, L / Anonymous130847. ·Cabinet d'ophtalmologie Breteuil, hôpital Lariboisière, AP-HP, université Paris Diderot, 14, avenue de Breteuil, 75007 Paris, France. Electronic address: massin.breteuil@gmail.com. · Hôpital Pasteur 2, CHU de Nice, université Nice - Sofia-Antipolis, 30, voie Romaine, 06000 Nice, France. · CHU de Dijon, université de Bourgogne, 14, rue Paul-Gaffarel, 21079 Dijon, France. · Centre d'imagerie et de laser, hôpital Avicenne, Bobigny - Paris XIII, 11, rue Antoine-Bourdelle, 75015 Paris, France. · CHU de la Croix-Rousse, hospices civils de Lyon, université Claude-Bernard - Lyon I, 103, Grande-Rue-de-la-Croix-Rousse, 69004 Lyon, France. ·J Fr Ophtalmol · Pubmed #26507784.

ABSTRACT: -- No abstract --